

SB 216763

Catalog No: tcsc0139



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

280744-09-4

Formula:

$C_{19}H_{12}Cl_2N_2O_2$

Pathway:

Stem Cell/Wnt;PI3K/Akt/mTOR;Autophagy

Target:

GSK-3;GSK-3;Autophagy

Purity / Grade:

>98%

Solubility:

H₂O :

Observed Molecular Weight:

371.22

Product Description


SB 216763 is potent and selective and ATP-competitive **glycogen synthase kinase-3 (GSK-3)** inhibitor, with an **IC₅₀** value of 34.3

nM for GSK-3 α and GSK-3 β , respectively.

IC50 & Target: IC50: 34.3 nM (GSK-3 α), 34.3 nM (GSK-3 β)^[5]

In Vitro: SB-216763 (10-20 μ M) induces β -catenin mediated-transcription in a dose-dependent manner in HEK293 cells. SB-216763 (10, 15 and 20 μ M) can maintain mESCs with a pluripotent-like morphology in long-term culture. SB-216763 (10 μ M) can maintain J1 mESCs in a pluripotent state for more than a month^[2]. SB-216763 inhibits GSK-3 with IC₅₀ of 34 nM^[3]. SB-216763 is equally effective at inhibiting human GSK-3 α and GSK-3 β ^[5].

In Vivo: SB216763 (20 mg/kg, i.v.) significantly improves the survival of BLM-treated mice. Mice randomized to receive BLM plus SB216763 shows a noteworthy reduction, compared with BLM-treated mice. SB216763 (20 mg/kg, i.v.) reduces the magnitude of BLM-induced alveolitis^[1]. SB 216763 (0.2 mg/kg, i.v.) with either 17 β -E₁₀₀ or Geni₁₀₀ reverses the ceiling effect because these agents significantly reduce infarct size when the rabbits' hearts are submitted to 30-min CAO^[4].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!